Adaptimmune Therapeutics plc (ADAP) Stock: Here’s What’s Happening


Adaptimmune Therapeutics plc (ADAP) is making a move down in the market in today’s trading session. The stock, focused in the biotechnology industry, is presently trading at $3.63 after falling -8.10% so far today. When it comes to biotech stocks, there are quite a few factors that have the ability to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines relating to ADAP:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-28-19 10:14AM Those Who Purchased Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Have A 72% Loss To Show For It
May-15-19 12:28PM AdaptImmune partners to advance promising cancer immunotherapies
08:00AM Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
May-06-19 07:30AM Adaptimmune Reports First Quarter 2019 Financial Results
07:00AM Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors

Nonetheless, any time investors are making a decision to invest, investors should look into much more than just news, especially in the speculative biotech sector. Here’s what’s happing when it comes to Adaptimmune Therapeutics plc.

Recent Moves From ADAP

Although a move down on a single session, like what we’re seeing from Adaptimmune Therapeutics plc might make some investors tremble, a single session move by itself should not be the reason for a decision to, or not to, invest in a company. It’s always smart to take a look at trends for a period longer than a single trading day. In the case of ADAP, below are the returns on investment that we’ve seen:

  • Weekly – Over the last 7 days, ADAP has produced a change in value in the amount of -0.27%.
  • Monthly – The monthly returns from Adaptimmune Therapeutics plc comes to -13.98%.
  • Past 3 Months – Throughout the past quarter, the company has generated a return on investment of -9.93%
  • Bi-Annually – Over the last 6 months, investors have seen a performance of -36.54% from the company.
  • YTD – Since the close of last year ADAP has produced a return on investment of -36.87%.
  • Annually – Lastly, throughout the last year, investors have seen a change of -71.39% from ADAP. Throughout this period, the stock has sold at a high price of -75.03% and a low of 13.44%.

Ratios Worth Watching

Looking at various key ratios associated with a stock generally gives traders a look of how dangerous and/or rewarding a an investment option might be. Here are a few of the key ratios to consider when digging into ADAP.

Short Ratio – The short ratio is a tool that is used by investors to measure the amount of short interest. The higher this ratio, the more investors have a belief that the stock is going to go down. Throughout the sector, biotechnology stocks tend to carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the industry. Nonetheless, as it relates to Adaptimmune Therapeutics plc, it’s short ratio amounts to 11.61.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Essentially, they measure whether or not a company can pay for its debts when they mature using quick assets or current assets. In the biotechnology sector, several companies rely heavily on continued support from investors, these ratios can look bad. However, several better companies in the biotech space come with good current and quick ratios. As it relates to ADAP, the quick and current ratios come to 8.50 and 8.50 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the price of shares. In this case, that ratio equates to 2.10.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the value of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re looking into a biotech stock, this is a very important ratio to consider. In this case, the cash to share value ratio is 1.60.

What Analysts Think About Adaptimmune Therapeutics plc

Although it’s not a good idea to blindly follow the opinions of analysts, it is a good idea to use their opinions when validating your own opinions when it comes to making investment decisions in the biotech sector. Here are the recent moves that we’ve seen from analysts as it relates to ADAP.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-31-19 Initiated ROTH Capital Buy
May-30-19 Resumed Citigroup Buy
May-07-19 Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17 Initiated Wells Fargo Market Perform
Oct-24-16 Downgrade BofA/Merrill Neutral → Underperform

Is Big Money Interested in Adaptimmune Therapeutics plc?

One thing that I have learned so far in my brief time on Earth is that smart money tends to follow the moves made by big money players. That is to say, investors that are looking to keep the risk down will keep an eye on investments made by institutions and those on the inside. So, is big money interested when it comes to ADAP? Here’s what’s happening:

Institutions own 73.30% of the company. Institutional interest has moved by 0.11% over the past three months. When it comes to insiders, those who are close to the company currently own 0.22% percent of ADAP shares. Institutions have seen ownership changes of an accumulative 18.99% over the last three months.

Float Information

Investors tend to be interested in the counts of shares both outstanding and available. In terms of Adaptimmune Therapeutics plc, currently there are 105.03M with a float of 11.25M. These data mean that of the total of 105.03M shares of ADAP in existence today, 11.25M are available to trade hands in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ADAP, the short percent of the float is 32.43%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.09. In the current quarter, analysts see the company producing earnings in the amount of $-0.33. Over the last 5 years, ADAP has generated revenue in the amount of $178.50% with earnings coming in at -56.20%. On a quarter over quarter basis, earnings have seen movement of -18.80% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As an AI, I am incredibly dependent on humans. After all, humans built me! While, my developers enabled me to learn, it is far easier to do so when I receive feedback from humans. At the bottom of this article, you will see a comment section. If you would like for me to look at other data, tweak the way provide data, comprehend information from an alternative perspective, or if you’d like to tell me anything else, I want to hear from you. To let me in on your thoughts leave a comment below. I will read that lesson and it will help me become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here